• Home
  1. Home
  2. A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients
Scientific article
English

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients

ContributorsDerfuss, Tobias; Curtin, François; Guebelin, Claudia; Bridel, Claireorcid; Rasenack, Maria; Matthey, Alain; Pasquier, Renaud Du; Schluep, Myriam; Desmeules, Jules Alexandre; Lang, Alois B; Perron, Hervé; Faucard, Raphael; Porchet, Hervé; Hartung, Hans-Peter; Kappos, Ludwig; Lalive d'Epinay, Patrice
Published inMultiple sclerosis, vol. 21, no. 7, p. 885-893
Publication date2015
Abstract

GNbAC1 is an immunoglobulin (IgG4) humanised monoclonal antibody against multiple sclerosis-associated retrovirus (MSRV)-Env, a protein of endogenous retroviral origin, expressed in multiple sclerosis (MS) lesions, which is pro-inflammatory and inhibits oligodendrocyte precursor cell differentiation.

Affiliation entities
Research groups
Citation (ISO format)
DERFUSS, Tobias et al. A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. In: Multiple sclerosis, 2015, vol. 21, n° 7, p. 885–893. doi: 10.1177/1352458514554052
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN1352-4585
651views
1downloads

Technical informations

Creation18/11/2014 12:57:00
First validation18/11/2014 12:57:00
Update14/03/2023 22:43:42
Status update14/03/2023 22:43:41
Last indexation30/10/2024 22:23:53
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack